BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25324403)

  • 1. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
    Mariya T; Hirohashi Y; Torigoe T; Asano T; Kuroda T; Yasuda K; Mizuuchi M; Sonoda T; Saito T; Sato N
    Cancer Immunol Res; 2014 Dec; 2(12):1220-9. PubMed ID: 25324403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
    Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
    J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.
    Lim W; Kim HS; Jeong W; Ahn SE; Kim J; Kim YB; Kim MA; Kim MK; Chung HH; Song YS; Bazer FW; Han JY; Song G
    PLoS One; 2012; 7(11):e49869. PubMed ID: 23185467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy.
    Shehata M; Mukherjee A; Deen S; Al-Attar A; Durrant LG; Chan S
    Br J Cancer; 2009 Oct; 101(8):1321-8. PubMed ID: 19755991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.
    Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
    Cancer Immunol Immunother; 2012 Aug; 61(8):1243-53. PubMed ID: 22258792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
    Wang Y; Li M; Meng F; Lou G
    Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.
    Aust S; Pils S; Polterauer S; Horvat R; Cacsire Castillo-Tong D; Pils D; Dudek G; Schmid B; Speiser P; Reinthaller A; Grimm C
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):518-24. PubMed ID: 23455184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
    Bachmayr-Heyda A; Aust S; Heinze G; Polterauer S; Grimm C; Braicu EI; Sehouli J; Lambrechts S; Vergote I; Mahner S; Pils D; Schuster E; Thalhammer T; Horvat R; Denkert C; Zeillinger R; Castillo-Tong DC
    BMC Cancer; 2013 Sep; 13():422. PubMed ID: 24044611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
    Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
    Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
    Previs R; Leath CA; Coleman RL; Herzog TJ; Krivak TC; Brower SL; Tian C; Secord AA
    Gynecol Oncol; 2015 Aug; 138(2):267-71. PubMed ID: 26037898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
    Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
    Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
    Miao Y; Li S; Yan Q; Li B; Feng Y
    Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
    Liu BL; Liu SJ; Baskys A; Cheng H; Han Y; Xie C; Song H; Li J; Xin XY
    BMC Cancer; 2014 Nov; 14():829. PubMed ID: 25399490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
    Li Y; Hu P; Cao Y; Wang GY; Wang N; Zhou RM
    Biomarkers; 2014 Mar; 19(2):128-34. PubMed ID: 24499239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.